Pharmaceuticals Stocks

Celgene Corporation Quarterly Valuation – February 2015 $CELG


Celgene is suitable for the Enterprising Investor, but not the more conservative Defensive Investor, who is concerned with the lack of dividends, lack of earnings stability over the last ten years, as well as the high PEmg and PB ratios. The Enterprising Investor, on the other hand, is only concerned by the lack of dividends. As a result, the Enterprising Investor should feel very comfortable proceeding to the next part of the analysis, which is a determination of the company’s intrinsic value.

From a valuation side of things, the company has grown its EPSmg (normalized earnings) from $0.23 in 2010 to $1.83 for 2015. This demonstrated growth is very strong but does not support the market’s implied estimate of 29.37% annual earnings growth over the next 7-10 years. The ModernGraham valuation model operates under the assumption that no company can sustain such a high level of growth over the long term and therefore returns an estimate of intrinsic value below the market price at this time, leading to the conclusion that the company is overvalued by the market.

Be sure to check out previous ModernGraham valuations of Celgene Corporation (CELG) for greater perspective!

Read the full valuation on Seeking Alpha!

CELG Chart

CELG data by YCharts

Disclaimer:  The author held a long position in Celgene Corporation (CELG) at the time of publication and had no intention of changing that position within the next 72 hours.  Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top